Interleukin-6 induces spatially dependent whole-body hypersensitivity in rats: implications for extracephalic hypersensitivity in migraine.

A. Avona¹, T.J. Price¹, G. Dussor¹

School of Behavioral and Brain Sciences, Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080¹

Corresponding Author: Gregory Dussor
ABSTRACT

**Background:** Migraine is a complex neurological disorder that is characterized by throbbing head pain, increased sensitivity to light, sound, and touch, as well as nausea and fatigue. It is one of the most common and most disabling disorders globally but mechanisms causing migraine are poorly understood. While head pain is a typical feature of attacks, they also often present with cutaneous hypersensitivity in the rest of the body. In contrast, pain conditions in the lower parts of the body do not generally lead to cutaneous hypersensitivity in the head. Previous studies indicate that application of stimuli to the meninges of rodents causes cutaneous facial as well as hindpaw hypersensitivity. In the present study, we asked whether widespread hypersensitivity is a unique feature of dural stimulation or whether body-wide responses occur similarly when the same stimulus is given in other locations.

**Methods:** Rats were given the same dose of IL-6 either via dural, intraplantar, subcutaneous, intramuscular, intracisternal, or intrathecal injection. Cutaneous facial and hindpaw allodynia was assessed using Von Frey following injection into each location.

**Results:** Hindpaw allodynia was observed following dural and intraplantar injection of IL-6 in both males and females. Hindpaw allodynia was only observed in females following intracisternal and intrathecal IL-6 injections. In contrast, facial alldynia was only observed in either sex following dural and intracisternal injections, which would activate meningeal afferents and the trigeminal nucleus caudalis (TNC), respectively.
Conclusions: Here we show that while stimulation of upper body regions with IL-6 including the meninges and brainstem can cause widespread hypersensitivity spreading to the paws, similar stimulation of the lower body does not cause the spread of hypersensitivity into the head. These data are consistent with the observations that whole body hypersensitivity is specific to conditions such as migraine where pain is present in the head and they may provide insight into co-morbid pain states associated with migraine.

Abbreviations: Interleukin-6 (IL-6), Trigeminal Ganglia (TG), Trigeminal Nucleus Caudalis (TNC), Toll-like Receptor 4 (TLR4), Calcitonin Gene-Related Peptide (CGRP), Δ1-9-G129R-hPRL (ΔPRL), Prolactin (PRL), Cortical Spreading Depression (CSD).

BACKGROUND

Migraine is among the top 10 most common disorders globally and is the 2nd-most disabling disease world-wide (1). Despite the prevalence of migraine, little is known about the pathophysiology. Migraine is characterized by throbbing head pain, cutaneous allodynia, nausea, and sensitivity to light and sounds. These symptoms vary among migraine patients, as do the triggers that spawn these attacks. Common triggers include stress, hormonal changes, changes in sleep-wake patterns, skipping meals, and consumption of alcohol and certain foods (2).

Migraineurs often report increased sensory sensitivity and cutaneous allodynia in extracephalic regions during migraine attacks (3-6). This is in contrast to other pain conditions
in the lower body which are not typically associated with hypersensitivity in the head. This suggests that migraine, and the concomitant activation of meningeal afferents that causes the headache phase, may have a distinctive circuitry that leads to widespread hypersensitivity. Numerous prior studies using rodent migraine models have shown a remarkably consistent finding that stimulation of the dura mater causes cutaneous hypersensitivity of both the facial skin as well as that of the hindpaw (7-11). These prior studies thus show that headache-inducing conditions lead to widespread hypersensitivity in rodents as in humans. While it is not generally reported that facial hypersensitivity exists in models of pain in the lower spinal system, these studies typically do not test for the presence of cephalic responses. The purpose of the present work was to test, using the same stimulus applied to multiple locations throughout the rat, whether dural stimulation is unique in its ability to cause body-wide hypersensitivity.

While migraine pathology remains poorly understood, inflammation is thought to be involved. Debate exists about the type, sites, and role of inflammation in migraine (12), but it is thought that peripheral inflammatory stimuli cause activation and hyper-excitability of meningeal afferents. These signals are received by the trigeminal ganglia, which sends these signals to higher order neurons in the trigeminal nucleus caudalis (TNC) (13). From the TNC, these signals are then processed by the cortex for the perception of head pain (14). One particular inflammatory mediator that has been implicated in migraine is interleukin-6 (IL-6). IL-6 is a pro-inflammatory cytokine that is upregulated in the serum and blood of migraine patients during an attack (15-17). We have shown previously that application of IL-6 on to the dura of female and male rats as well as mice results in cutaneous facial allodynia (7, 18, 19).
Importantly, these studies also showed that IL-6 applied to the rodent dura causes facial and hindpaw allodynia (7, 10). Additionally, this same dose of IL-6 given onto the dura is capable of sensitizing male and female rats to respond to subthreshold doses of migraine relevant triggers such as lowered dural pH and dural calcitonin gene-related peptide (CGRP) (7, 18). Furthermore, we have shown that IL-6 applied to the dura of male rats causes facial and hindpaw allodynia (7, 10). Based on the link between IL-6 and migraine and headache-relevant behavioral responses in preclinical models with dural IL-6, we chose this stimulus as the probe to test whether activation of meningeal afferent neurons can cause differential spread of hypersensitivity compared to the same stimulus given elsewhere.

METHODS:

Animals:

In this study, 12-14 week-old approx. 260-300g female and approx. 300-350g male Sprague-Dawley rats (Taconic; Rensselaer, NY) were used for all experiments. Animals were housed on a 12-hour light/dark cycle with access to food and water ad libitum. Animals were housed in the facility for at least 72 hours prior to handling and habituation of animals to testing rooms. All procedures were conducted with prior approval of the Institutional Animal Care and Use Committee at the University of Texas at Dallas.
Rat Cannula implantation and drug delivery:

Dural injections in rats were administered via cannula at a total of 10 µl injections. Animals were anesthetized initially at 5% isoflurane via a nose cone; once animals no longer demonstrated a paw pinch reflex, isoflurane was lowered to 2.5-3.5% for the entirety of the surgery. The scalp was incised longitudinally and retracted from the midline to expose the skull. Using a pin vise (Grainger Industries) set to a length of 1 mm, a 1 mm burr hole was created using a stereotaxic frame at the target coordinates to sit above the middle meningeal artery (8mm AP, -2mm ML, 1mm DV) to puncture the skull while leaving the dura intact. A guide cannula (Plastics One C313G/SPC gauge 22) was implanted into the burr hole using a stereotaxic frame and sealed using Vetbond (Vetbond). Two screws were inserted above the guide cannula on both sides of midline below bregma. Perm reline repair resin (Coltene, Altstätten, Switzerland) was used to anchor the cannula to the screws and skull. To prevent clogging, a dummy cannula (Plastics One 313DC-SPC 0.014-0.36mm fit 1 mm) was inserted into the guide cannula. Post-surgery, animals were given 8 mg/kg gentamicin and 0.25 mg meloxicam, to prevent infection and for pain management, respectively. Animals were returned to their home cage and allowed to recover for 7 days.

Intraplantar injections:

Intraplantar injections were administered according to previously published methods (18). Briefly, rats were anesthetized initially at 5% isoflurane via a nose cone, once animals no longer exhibited a pinch reflex, isoflurane was lowered to 2.5-3%, during which time animals were
injected. These animals received a volume of 50 µl into the left hindpaw via injection with a 30-gauge 0.5 inch needle attached to a Hamilton syringe. Animals were kept under isoflurane for <2 minutes.

**Intracisternal Injections:**

Intracisternal injections were administered in a volume of 10 µl at a rate of 1 µl/sec and performed as previously described (20). A 25-gauge 1.5 inch needle was contorted approximately 7 mm from the tip at a 45° angle with the bevel facing outwards. The needle was attached to a 27-gauge Hamilton syringe. Animals were anesthetized for < 2 minutes under 2.5-3% isoflurane via a nose cone. The head of the animal was tilted forward at approximately a 120° angle to allow access to the cisterna magna. The needle was positioned above C1 and inserted through the cisterna magna along the midline.

**Intrathecal injections**

Intrathecal injections were performed according to previously published methods (21). Injections were performed into the L5-L6 intervertebral space while animals were under 2.5-3% isoflurane administered via a nose cone. Injections were administered using a 30-gauge 0.5 inch needle.

**Von Frey testing**
Rats were allowed to acclimate to testing room, chambers, and light conditions for 2 hours a day for 3 days prior to facial testing. Rats were handled for a single 5-min session at 24-hours prior to habitation to the behavior chambers. Only rats that met a baseline of 8 g facial withdrawal threshold and 15 g hindpaw withdrawal threshold were included in the study. Following establishment of baseline, animals were given their respective injections. Facial withdrawal thresholds were determined by applying von Frey filaments to the periorbital region of the face (the midline of the forehead at the level of the eyes) in an ascending/descending manner starting from the 1 g filament. Briefly, if an animal did not respond, increasing filament forces were applied until the 8 g filament was reached or until a response was observed. If the animal responded to a specific filament, decreasing filament forces were applied until the 0.4 g filament was reached or until there were no responses observed. Hindpaw withdrawal thresholds were determined via the same paradigm with a maximum of beginning with the 2 g filament and with a maximum of 15 g and a minimum of 0.6 g.

**Drugs:**

Rat recombinant IL-6 (R&D systems, cat: 506-RL-050/CF) was diluted in synthetic interstitial fluid (SIF) comprised of 135 mM NaCl, 5 mM KCl, 10mM HEPES, 2mM CaCl2, 10mM glucose, and 1mM MgCl2 (pH 7.4, 310 mOsm) for dura, hindpaw, and gastrocnemius muscle injections. For intracisternal injections IL-6 was diluted in artificial cerebrospinal fluid (aCSF) which was comprised of 125mM NaCl, 26mM NaHCO3, 1.25mM NaH2PO4, 2.5mM KCl, 1mM MgCl2, 2mM CaCl2, and 10mM D-glucose (pH 7.4). For intrathecal injection IL-6 was diluted in 0.9% saline. Diluents were used as respective vehicles for all experiments.
Experimental design and statistical analysis:

In all experiments, investigators were blinded to treatment groups. Allocation of animals to treatment groups was randomized via the “blinder” who chose animal identification numbers from a bag of pre-labeled paper slips. Data here are presented as mean ± SEM. Data were analyzed at each time point via two-way ANOVA and followed by Bonferroni post-hoc assessment where appropriate. Prism (GraphPad) was used for all data analyses. Significance was set to p< 0.05 for all analyses.

RESULTS:

Dural IL-6 causes facial and hindpaw sensitivity in female rats.

Previously we found that application of IL-6 onto the dura of male rats not only resulted in facial hypersensitivity, but hindpaw sensitivity (7). While we have additionally reported that dural IL-6 leads to facial allodynia in females (7), we did not test the ability of this stimulus to cause whole body allodynia in females. Given that cutaneous allodynia is more common in female migraineurs (22, 23) we aimed to test whether female rats would experience hindpaw allodynia similarly to male rats. Here we confirm that female rats that receive dural IL-6 demonstrate facial allodynia out to 72 hours (Fig. 1A), and additionally experience significant hindpaw sensitivity, persisting for 24 hours following injection (Fig. 1B).

Intraplantar administration of IL-6 results in hindpaw, but not facial, allodynia.
Our data here and in our prior publications indicates that dural stimulation with IL-6 causes referred hypersensitivity to the hindpaw. Previously we have reported that intraplantar IL-6 leads to sensitivity in the hindpaw (7). We next sought to test whether intraplantar IL-6 causes periorbital hypersensitivity like that observed following dural IL-6. Both sexes were tested since females and males exhibit differential responses to migraine-relevant peptides in multiple peripheral tissues including the hindpaw (18, 24). Both female and male rats received 0.1 ng IL-6 into the left hindpaw and were subject to periorbital and hindpaw von Frey testing. Females demonstrated acute hindpaw allodynia at 1 and 3 hours following injection (Fig. 2), consistent with hindpaw responses shown previously with intraplantar IL-6 in males (7). In contrast, neither females nor males exhibited any facial hypersensitivity responses at any time point following intraplantar IL-6 (Fig. 3). These data demonstrate that while dural IL-6 causes referred hypersensitivity to the hindpaw, intraplantar IL-6 does not cause referred hypersensitivity to the facial skin.

**Subcutaneous IL-6 in the scalp does not elicit facial or hindpaw hypersensitivity.**

Prior studies have found that migraine-relevant peptides injected into the periorbital region of the face of rats results in facial alldynia (25). This is likely due to activation of fibers from the trigeminal ganglia that innervate the peri-orbital region of the face i.e. direct activation and sensitization of nerve endings near the site of von Frey testing. In contrast, for dural stimulation to cause periorbital hypersensitivity, central sensitization leading to referred responses from the dura to the facial skin must be present. This led us to question whether the periorbital hypersensitivity that results from 0.1 ng dural IL-6 would be observed if this stimulus
was applied subcutaneously to the scalp where the dural cannula would otherwise be implanted. Thus, we administered subcutaneous IL-6 to the rostral part of the scalp in rats that were otherwise naïve, i.e., they had no dural cannula. Despite the noted projection of dural afferents to the extracranial periosteum (26), neither females nor males exhibited any periorbital (Fig. 4A, C) or hindpaw (Fig. 4B, D) hypersensitivity at any time point following subcutaneous IL-6. These data show that the referred periorbital hypersensitivity that develops following activation of dural afferents is not a general response to IL-6 injected anywhere in the head.

**Injection of IL-6 into the gastrocnemius muscle fails to produce facial or hindpaw hypersensitivity in male or female rats.**

Peripheral cutaneous injections into the scalp produced no facial or hindpaw hypersensitivity, suggesting that whole body responses are not simply caused by general activation of the afferents within trigeminal system. One alternate possibility is that widespread referred responses are caused by activation of deep-tissue afferents but not cutaneous afferents. This is a well-known phenomenon observed with gastrointestinal or cardiac pain that is commonly referred to the surface of the abdomen. It is possible that hindpaw and scalp injections of IL-6 do not cause widespread referred hypersensitivity since they are subcutaneous while stimulation of the dura mater is more similar to activation of deep-tissue afferents. To address this possibility, we administered 0.1 ng IL-6 into the gastrocnemius muscle. We observed no significant reductions in facial or hindpaw withdrawal response to this intramuscular injection in either female (Fig. 5A, B) or male rats (Fig. 5C, D). This indicates that the referred
hypersensitivity of the facial and hindpaw skin following dural stimulation with IL-6 is not a
generalized response to activation of non-cutaneous afferents.

**Intracisternal IL-6 produces facial and hindpaw hypersensitivity in rats.**

It has been shown previously that dural application of inflammatory soup (IS) can lead to
sensitization of neurons within the TNC (13, 27, 28). This sensitization that develops has been
suggested to be the underlying mechanism of referred facial hypersensitivity following dural
stimulation. We thus aimed to determine whether direct stimulation of the central terminals of
trigeminal afferents or of second-order neurons within the TNC with IL-6 would produce whole
body hypersensitivity. To test this, rats received 0.1 ng IL-6 into the cisterna magna. Female rats
exhibited facial (Fig. 6A) and hindpaw (Fig. 6B) hypersensitivity at 3 hours following injection.
Male rats exhibited no hindpaw hypersensitivity (Fig. 6D) but demonstrated significant facial
allodynia from 1 to 5 hours following injection (Fig. 6C). These data show that activation of
circuits within the brainstem by IL-6 is capable of causing referred facial hypersensitivity, and
also referred paw hypersensitivity in females, but that only dural stimulation causes referred
paw hypersensitivity in males.

**Intrathecal IL-6 causes hindpaw hypersensitivity in females.**

The findings showing that intracisternal injection of IL-6 leads to whole body hypersensitivity, at
least in females, led us to question whether central sensitization in general leads to widespread
hypersensitivity, or whether this is specific to the activation of the trigeminal pathways. To
address this question, we administered 0.1 ng IL-6 intrathecally in both male and female rats. IL-6 produced significant acute hindpaw hypersensitivity in females 1 hour following injection (Fig. 7B). No hindpaw hypersensitivity was observed in males at any time point (Fig. 7D). Importantly, no facial hypersensitivity responses were observed in either sex at any time point (Fig. 7A, C). These findings show that referred hypersensitivity to the periorbital region is not a general feature of injections of IL-6 into the spinal canal but that it is unique to activation of meningeal afferents or the TNC.

DISCUSSION:

While many migraine patients report cutaneous hypersensitivity in cephalic and in one or multiple additional extracephalic sites during attack (3-5), it is less common that patients with pain states in the lower part of the body experience cephalic hypersensitivity. Little is known about how or why this occurs. Here we examined whether a similar effect occurs in rats where provoking migraine-like conditions causes body wide hypersensitivity and whether these widespread responses are absent when the same stimulus is given into locations that would cause other types of pain. We used the pro-inflammatory cytokine IL-6, which is upregulated during migraine attacks, but is a stimulus that is also implicated in pain states in other body regions (29). IL-6 administered directly onto the dura of female rats results in facial and hindpaw hypersensitivity similarly to our previous reports in male rats (7). In contrast, intraplantar IL-6 at the same dose only produces hindpaw responses in either females or males. Subcutaneous IL-6 onto the scalp produced no facial or hindpaw allodynia in either sex. We also show that IL-6 administered intracisternally produces facial hypersensitivity in both sexes, but only leads to whole body responses in females. Finally, when IL-6 was administered
intrathecally, neither males nor females exhibit facial hypersensitivity, but females demonstrated significant decreases in hindpaw withdrawal thresholds.

Together, these data show that the only locations where administration of IL-6 leads to periorbital hypersensitivity is onto the dura or via intracisternal injection, the latter of which is capable of activating central trigeminal pathways for all innervation targets. These are also the only stimulus locations where hypersensitivity is referred to distant locations across the body. This finding suggests the presence of unique pathways through the trigeminal system that are capable of establishing widespread behavioral responses and that similar pathways do not exist within the lower spinal system. These data may help to offer additional insight into the mechanistic differences by which meningeal afferents and other sensory inputs engage central circuits to cause pain and also may aid in the understanding of how and why migraine is such a debilitating disorder.

The data presented here show a robust ability of dural stimulation with IL-6 to cause both facial and hindpaw hypersensitivity, demonstrating a role for meningeal inputs in these responses. However, intracisternal injection of IL-6 should activate these dural inputs in addition to many, if not all, other trigeminal inputs to the TNC. Thus, it is surprising that intracisternal IL-6 did not cause hindpaw hypersensitivity in males. These data may be due to the release of additional inflammatory mediators or other signaling molecules downstream of dural IL-6 that are not present following intracisternal IL-6, ultimately adding to the stimulus intensity of the former. For example, there may be release of factors such as histamine, serotonin, proteases, and other sensitizing agents from mast cells (30, 31). Given that mast cells are more abundant in the dura mater and leptomeninges (32), the release of additional inflammatory mediators from these
cells may lead to increased engagement of trigeminal pathways in response to dural IL-6. This may also explain why the facial hypersensitivity responses of males and females to intracisternal IL-6 are less robust and of shorter duration than those resulting from dural application.

We also surprisingly observed that while subcutaneous IL-6 on the scalp failed to produce hindpaw hypersensitivity, consistent with IL-6 injections into numerous other locations, it was also unable to cause hypersensitivity of the relatively nearby periorbital skin. This is despite the fact that the scalp IL-6 injection should activate or sensitize dural fibers in the periosteum that pass through the calvarial sutures (33). Activation of these fibers has previously been demonstrated with stimuli such as KCl and inflammatory soup (34). In contrast, capsaicin and low pH 5.0 failed to activate these afferents reliably or robustly (34). It is thus possible that not all stimuli are able to activate these fibers and IL-6 may be among those that cause no responses. Additionally, the location of subcutaneous scalp injection may not effectively target these periosteal trigeminal afferents directly.

While many of the responses to IL-6 shown here were not sexually dimorphic, there were several notable exceptions. We show that intrathecal administration of IL-6 only leads to hindpaw responses in female rats (Fig. 6). Similarly, IL-6 applied into the cisterna magna resulted in facial hypersensitivity in both females and males, but only led to hindpaw hypersensitivity in females (Fig. 5). Prior studies show that estrogen can lead to inhibition of IL-6 production and release (35, 36), but whether this leads to changes in effects of exogenous IL-6 is not clear. Recently, a potential role for spinal prolactin (PRL) has been implicated in the production of IL-6 induced hindpaw alldynia (24), as intrathecal administration of a prolactin
receptor antagonist (ΔPRL) prevents responses to IL-6 in female mice. Similarly, co-injection of PRL with IL-6 increases hindpaw hypersensitivity in female mice. The increased endogenous levels of PRL in females rats compared to their male counterparts (37-39) may explain the ability of intracisternal and intrathecal IL-6 to produce hindpaw responses in females, but not in males at this dose, as it may be a more intense stimulus in females. These findings also demonstrate a clear role for the trigeminal system in producing whole body hypersensitivity; central administration of IL-6 to the TNC leads to whole body allodynia, while central administration that does not activate the trigeminal system is incapable of eliciting a facial response.

There are several potential limitations to this study. The only stimulus tested was IL-6 and other migraine-relevant stimuli may lead to differential responses across the body; in particular, other stimuli applied to the lower body may lead to facial hypersensitivity. However, we have previously demonstrated that hindpaw injection of CGRP leads to hindpaw allodynia in female rats, but does not result in any facial hypersensitivity (18). Next, while we did not observe widespread hypersensitivity when IL-6 was injected subcutaneously into the scalp, there may have been different findings with IL-6 injected into other trigeminal targets such as the temporomandibular joint. Stimulation of other such tissues may be more effective at referring hypersensitivity to the facial skin. Similarly, we used the gastrocnemius muscle as a representative deep tissue, but injection of IL-6 may lead to more robust and widespread referred pain from other deep tissues such as visceral organs. While colonic inflammation has been shown to induce periorbital hypersensitivity in rodents, this model required
administration of dextran sodium sulfate into the drinking water for 7 days and the location of action leading to periorbital hypersensitivity is not clear (40). Finally, IL-6 administration at this dose leads to transient behavioral responses that may better reflect signaling pathways associated with acute pain states. Testing chronic pain models in other body locations may lead to more widespread hypersensitivity, including into the facial region.

Overall, these data show the unique ability of dural and intracisternal stimulation to produce robust whole-body hypersensitivity and are consistent with the building list of studies supporting differential connections of trigeminal and dural pathways with central circuits relevant for pain. These studies raise the possibility that afferent input from the head may more effectively engage central pain and affective circuits as an enhanced protective mechanism given the importance of the brain and other sensory structures within the head. Similarly, hypotheses have been proposed that migraine evolved as a defense mechanism, and to lead to detection of potentially harmful events such as the ingestion of toxins, lack of sleep, or hunger (41). They further support the notion that all forms of pain have evolved to contribute to the survival of an organism (42). This idea also offers context to the common symptoms, and diagnostic criteria for migraine, photophobia and phonophobia where the increased sensitivity to lights and sounds would signal for the animals to remain in a covered location, to become less susceptible to predators (43). In the case of rodents, they often remain immobile to heal and recover, therefore the hindpaw allodynia we observe here in response to dural and intracisternal stimulation may serve to prevent the animal from moving. This is
consistent with findings that cortical spreading depression (CSD) leads to significant freezing behavior in rats (44). Furthermore, this freezing behavior is attenuated by CGRP inhibitors (44).

CONCLUSIONS:

The findings of this study show that activation of trigeminal afferents, and in particular dural afferents, are uniquely able to generate widespread cutaneous hypersensitivity in both female and male rats. Mechanisms underlying these effects may contribute to the distinct collection of symptoms present in pain states such as migraine where sensory symptoms spread beyond the cephalic region. Better understanding of these mechanisms may lead to novel therapeutic approaches that are differentially effective for migraine compared to pain in the rest of the body.

DECLARATIONS:

Ethics approval and consent to participate: All procedures were conducted with prior approval of the Institutional Animal Care and Use Committee at the University of Texas at Dallas.

Consent for publication: Not applicable.

Availability of data and materials: Raw data are available upon request via contacting the corresponding author: Gregory.Dussor1@utdallas.edu/
Competing interests: Not applicable.

Funding: This work was supported by National Institutes of Health grants NS072204 (GD) and NS104200 (GD and AA).

Authors Contributions: Design of work: AA, TJP, GD,

Acquisition and analysis of work: AA

Interpretation of data: AA, GD

Draft of the manuscript: AA, GD

Acknowledgements: We would like to acknowledge Nandita Ramkumar for technical work.

1. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-59.
2. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394-402.
3. Mathew NT, Kailasam J, Seifert T. Clinical recognition of alodynia in migraine. Neurology. 2004;63(5):848-52.
4. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123 ( Pt 8):1703-9.
5. Tietjen GE, Brandes JL, Peterlin BL, Eloff A, Dafer RM, Stein MR, et al. Alodynia in migraine: association with comorbid pain conditions. Headache. 2009;49(9):1333-44.
6. Plesh O, Adams SH, Gansky SA. Self-reported comorbid pains in severe headaches or migraines in a US national sample. Headache. 2012;52(6):946-56.
7. Burgos-Vega CC, Quigley LD, Avona A, Price T, Dussor G. Dural stimulation in rats causes brain-derived neurotrophic factor-dependent priming to subthreshold stimuli including a migraine trigger. Pain. 2016;157(12):2722-30.
8. Wieseler J, Ellis A, Sprunger D, Brown K, McFadden A, Mahoney J, et al. A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats. J Neurosci Methods. 2010;185(2):236-45.
9. Edelmayer RM, Ossipov MH, Porreca F. An experimental model of headache-related pain. Methods Mol Biol. 2012;851:109-20.
10. Yan J, Melemedjian OK, Price TJ, Dussor G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain. 2012;8:6.
11. Oshinsky ML, Gomonchareonsiri S. Episodic dural stimulation in awake rats: a model for recurrent headache. Headache. 2007;47(7):1026-36.
12. Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15(8):483-90.
13. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79(2):964-82.
14. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622.
15. Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C, Pierguidi L, et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006;46(2):200-7.
16. Fidan I, Yuksel S, Ymir T, Irkec C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol. 2006;171(1-2):184-8.
17. Yucel M, Kotan D, Guroh Ciftci G, Ciftci IH, Cikriklar H. Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci. 2016;20(5):930-6.
18. Avona A, Burgos-Vega C, Burton MD, Akopian AN, Price TJ, Dussor G. Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine Models. J Neurosci. 2019;39(22):4323-31.
19. Burgos-Vega CC, Quigley LD, Trevisan Dos Santos G, Yan F, Asiedu M, Jacobs B, et al. Non-invasive dural stimulation in mice: A novel preclinical model of migraine. Cephalalgia. 2019;39(1):123-34.
20. Chen Y, Imai H, Ito A, Saito N. Novel modified method for injection into the cerebrospinal fluid via the cerebellomedullary cistern in mice. Acta Neurobiol Exp (Wars). 2013;73(2):304-11.
21. Mestre C, Pelissier T, Fialip J, Wilcox G, Eschalier A. A method to perform direct transcortaneous intrathecal injection in rats. J Pharmacol Toxicol Methods. 1994;32(4):197-200.
22. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Servano D, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008;70(17):1525-33.
23. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148-58.
24. Patil M, Belugin S, Mecklenburg J, Wangzhou A, Pai C, Barba-Escobedo PA, et al. Prolactin Regulates Pain Responses via a Female-Selective Nociceptor-Specific Mechanism. iScience. 2019;20:449-65.
25. De Logu F, Landini L, Janal MN, Li Puma S, De Cesaris F, Geppetti P, et al. Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain. 2019;20(1):18.
26. Schueler M, Neuhuber WL, De Col R, Messlinger K. Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents. Headache. 2014;54(6):996-1009.
27. Oshinsky ML. Sensitization and ongoing activation in the trigeminal nucleus caudalis. Pain. 2014;155(7):1181-2.
28. Bartsch T, Goadsby PJ. Increased responses in trigemino-cervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain. 2003;126(Pt 8):1801-13.
29. Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, et al. Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation. 2016;13(1):141.
30. Conti P, Kempuraj D, Di Gioacchino M, Boucher W, Letourneau R, Kandere K, et al. Interleukin-6 and mast cells. Allergy Asthma Proc. 2002;23(5):331-5.
31. Theoharides TC, Alyssandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21-33.
32. Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy? J Neuroimmunol. 2002;131(1-2):5-20.
33. Schueler M, Messlinger K, Dux M, Neuhuber WL, De R. Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache. Pain. 2013;154(9):1622-31.
34. Zhao J, Levy D. The sensory innervation of the calvarial periosteum is nociceptive and contributes to headache-like behavior. Pain. 2014;155(7):1392-400.
35. Canellada A, Alvarez I, Berod L, Gentile T. Estrogen and progesterone regulate the IL-6 signal transduction pathway in antibody secreting cells. J Steroid Biochem Mol Biol. 2008;111(3-5):255-61.
36. Kassem M, Harris SA, Spelsberg TC, Riggs BL. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. J Bone Miner Res. 1996;11(2):193-9.
37. Neill JD. Effect of "stress" on serum prolactin and luteinizing hormone levels during the estrous cycle of the rat. Endocrinology. 1970;87(6):1192-7.
38. Dohler KD, Wuttke W. Changes with age in levels of serum gonadotropins, prolactin and gonadal steroids in prepubertal male and female rats. Endocrinology. 1975;97(4):898-907.
39. Voogt JL, Chen CL, Meites J. Serum and pituitary prolactin levels before, during, and after puberty in female rats. Am J Physiol. 1970;218(2):396-9.
40. Jain P, Materazzi S, De Logu F, Rossi Degl’Innocenti D, Fusi C, Li Puma S, et al. Transient receptor potential ankyrin 1 contributes to somatic pain hypersensitivity in experimental colitis. Sci Rep. 2020;10(1):8632.
41. Loder E. What is the evolutionary advantage of migraine? Cephalalgia. 2002;22(8):624-32.
42. Walters ET, Williams ACC. Evolution of mechanisms and behaviour important for pain. Philos Trans R Soc Lond B Biol Sci. 2019;374(1785):20190275.
43. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
44. Filiz A, Tepe N, Eftekhar S, Boran HE, Dilekoz E, Edvinsson L, et al. CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia. 2019;39(3):354-65.
FIGURES AND LEGENDS:

Figure 1. Dural IL-6 produces facial and hindpaw hypersensitivity in females. Female rats had baseline withdrawal thresholds established prior to receiving administration of 0.1 ng IL-6 onto the dura. Dural IL-6 (n=10) elicited significant effect of treatment on facial (A) $F(1, 66) = 31.58$, $p<0.0001$ and hindpaw (B) $F(1, 66) = 43.66$, $p<0.0001$ hypersensitivity when compared with animals that received vehicle (n=4). *$p<0.05$, ****$p<0.0001$.

Figure 2. Intraplantar IL-6 produces hindpaw hypersensitivity in females. Female rats from the cohort in figure 2 also had baseline hindpaw withdrawal thresholds established prior to receiving intraplantar injection of 0.1 ng IL-6. IL-6 (n=6) elicited significant effect of treatment on hindpaw hypersensitivity ($F(5, 60) = 2.512$, $p=0.0394$) when compared with animals that received vehicle (n=6). *$p<0.05$, ***$p<0.001$.

Figure 3. Intraplantar administration of IL-6 produces no facial responses in female or male rats. Female and male rats had facial hindpaw withdrawal thresholds assessed prior to and following intraplantar injection of 0.1 ng IL-6 (6 females, 6 males) or vehicle (6 females, 6 males). Two-way ANOVA followed by Bonferroni posthoc analysis revealed no significant facial responses in female (A) ($F(1, 40) = 1.844$, $p=0.1821$) or male (B) (no variation among groups) rats.

Figure 4. Subcutaneous injection of IL-6 in the scalp produces no significant facial or hindpaw responses in male and female rats. Rats had facial and hindpaw withdrawal thresholds assessed to establish baseline withdrawal thresholds, as well as following administration of 0.1 ng IL-6 (6 females, 8 males) or vehicle (7 females, 6 males) subcutaneously in the scalp. Two-way ANOVA followed by Bonferroni posthoc analysis revealed no significant facial or hindpaw responses in female (A, B) ($F(1, 44) = 0.2761$, $p=0.6019$) (F (1, 44) = 1.502, $p=0.2269$) or male (C,D) (no variation among groups) ($F(1, 48) = 1.371$, $p=0.2473$) rats.
Figure 5. Gastrocnemius injection of IL-6 produces no significant facial or hindpaw responses in male and female rats. Rats had facial and hindpaw withdrawal thresholds assessed prior to and following administration of 0.1 ng IL-6 (6 females, 6 males) or vehicle (6 females, 5 males) into the gastrocnemius muscle. Two-way ANOVA followed by Bonferroni posthoc analysis revealed no significant effect of treatment on facial or hindpaw responses in female (A, B) (F (1, 40) = 1.844, p=0.1821) (F (3, 36) = 0.2904, p=0.8320) or male (C, D) (no variation among groups) (F (1, 36) = 2.289, p=0.1390) rats.

Figure 6. Intracisternal IL-6 produces facial hypersensitivity in both sexes, but differential hindpaw responses. Female (A, B) and male (C, D) rats had baseline withdrawal thresholds of the face and hindpaw determined prior to intracisternal injection of IL-6 (4 females, 6 males) or vehicle (5 females, 7 males). Both females and males demonstrated significant effects of treatment on facial responses (F (1, 35) = 12.24, p=0.0013) (F (1, 55) = 27.98, p<.0001); however, only females presented with hindpaw responses. (F (1, 35) = 9.640, p=0.0038) *p<0.05, ****p<0.0001.

Figure 7. Intrathecal IL-6 produces hindpaw responses in female, but not male rats. Rats had periorbital and hindpaw withdrawal thresholds assessed prior to and following intrathecal administration of 0.1 ng IL-6 (6 females, 6 males) or vehicle (6 females, 6 males). Two-way ANOVA followed by Bonferroni posthoc analysis revealed no significant effect of treatment on facial responses in female (A, B) (F (1, 40) = 2.924, p=0.0950) or male (C, D) rats (F (1, 40) = 1.280, p=0.7223). Female rats demonstrated significant hindpaw allodynia. (F (1, 40) = 8.700, p=0.0053) **p<0.01.